Wall Street Analysts And Options Market Suggest AbbVie Has Upside


  • There is widespread concern about the impact of Humira biosimilars being available in the U.S.
  • The consensus outlook is that ABBV’s earnings will decline.
  • The Wall Street consensus rating is a buy, with a consensus price target that corresponds to 15% in total return.
  • The market-implied outlook (calculated from options prices) has gotten more bullish since September.
Abbott and Abbvie sign at their headquarters in Abbott Park, IL, USA.


In early 2023, Amgen (AMGN) entered the U.S. market with a biosimilar drug to AbbVie’s (NYSE:ABBV) Humira. Humira has been the best-selling drug in the world for the past 10 years and is expected to become the

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *